| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b882006e755dfc56fcabfc5fb019f6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4355 |
| filingDate |
2017-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d514d001ce21c69a3381f106a94164f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f64546d6b897c2f8ff61aafada478e85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97c52bc7859a8b5d48083fef9cc6f872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edaa98532832c887c8e4d8dae8f4a304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c9470146ae3f5649c487e9a230967ee |
| publicationDate |
2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2017278102-B2 |
| titleOfInvention |
Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| abstract |
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure ( |
| priorityDate |
2016-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |